Silk Road Medical said today it raised $47 million in a new funding round to support its Enroute products designed for transcarotid artery revascularization procedures.
The round was led by newly invested Norwest Venture Partners and Janus Capital Management funds and joined by existing investors Warburg Pincus, The Vertical Group and CRG, the Sunnyvale, Calif.-based company said.
Silk Road’s Enroute neuroprotection system is designed to allow physicians direct access to the common carotid artery in the neck to initiate high rate temporary blood flow reversal to protect the brain from stroke during implantations of its Enroute transcarotid stent.
“TCAR represents one of the next potential multi-billion dollar medical device markets, and Silk Road is eponymous with the category with a sustainable advantage. With 13 million ischemic strokes occurring annually and carotid artery disease the culprit in up to one third of cases, the opportunity for TCAR is tremendous,” Janus Henderson Investors’ Ethan Lovell said in a prepared statement.
Read More: http://www.massdevice.com/silk-road-medical-raises-47m/